Table 1.
Study | Year | Follow Up (m) | Total Patients | Patient With AF | Patients With NSR | Age (y) | Male (%) | ICD Indication | LVEF (%) | AA in AF (%) | AA in NSR (%) | NYHA in AF | NYHA in NSR | Quality Assessmenta |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Madhavan et al8 | 2016 | 40 | 253 | 115 | 138 | 68.3 | NS | PP | 32 | ··· | ··· | <3: 85b, ≥3: 15 | Good | |
Grönefeld et al9 | 2000 | 20 | 229 | 38 | 191 | 64 | 82 | Unspecified | 37 | 21 | 13 | NS | NS | Good |
Rienstra et al10 | 2007 | 31 | 290 | 83 | 207 | 63 | 81 | PP/SP | 29 | 45 | 36 | <3: 84, ≥3: 16 | <3: 90, ≥3: 10 | Good |
Borleffs et al11 | 2010 | 28 | 913 | 250 | 663 | 67 | 79 | PP/SP | 32 | 24 | 10 | <3: 55, ≥3: 45 | <3: 66, ≥3: 34 | Good |
Deneke et al12 | 2004 | 9.5 | 359 | 68 | 291 | 62.8 | 81 | PP/SP | 39 | 37.3 | 24.8 | <3: 81, ≥3: 29 | <3: 83, ≥3: 17 | Good |
van Gelder et al4 | 2011 | 31 | 537 | 133 | 404 | 71 | 79 | PP | 28 | 20 | 11 | NS | NS | Good |
Köbe et al13 | 2013 | 14 | 3261 | 607 | 2654 | 70.9 | 82 | PP/SP | 31 | 17.2 | 14.7 | <3: 78, ≥3: 22 | <3: 84, ≥3: 16 | Good |
Smit et al14 | 2006 | 8 | 80 | 29 | 51 | 63 | 79 | PP | 24 | 24 | 18 | <3: 55, ≥3: 45 | <3: 51, ≥3: 39 | Good |
Zareba et al15 | 2006 | 20 | 655 | 61 | 594 | 65 | NS | Unspecified | ··· | 14 | 5 | 2 to 4:73 | 2 to 4: 63 | Good |
van Rees et al16 | 2011 | 60 | 1544 | 355 | 1189 | 61 | 79 | PP/SP | 35 | 20b | ··· | <3: 67b, ≥3: 33 | Good | |
Bunch et al17 | 2009 | 12 | 1530 | 174 | 1356 | 68.7 | 81 | Unspecified | ··· | 27 | 7.2 | <3: 71, ≥3: 29 | <3: 76, ≥3: 24 | Good |
Kraaier et al18 | 2013 | 41 | 647 | 183 | 464 | 64 | 81 | Unspecified | ··· | ··· | ··· | NS | NS | ··· |
Ryan et al19 | 2001 | 24 | 321 | 92 | 229 | 65 | NS | Unspecified | ··· | ··· | ··· | NS | NS | ··· |
Marijon et al20 | 2010 | 22 | 1030 | 277 | 753 | 63 | 89 | PP/SP | 36 | 54b | ··· | NS | NS | Good |
Schernthaner et al21 | 2007 | 24.5 | 77 | 32 | 45 | 66 | NS | PP/SP | 34 | 13b | ··· | <3: 65b, ≥3: 35 | Good | |
Desai et al6 | 2010 | 40 | 549 | 70 | 479 | 74 | NS | PP | 29 | 32b | ··· | 2 to 3: 69b, 4: 31 | Good | |
Schefer et al22 | 2008 | 51 | 157 | 22 | 135 | 53 | 78 | PP/SP | 40 | 45b | ··· | <3: 74b, ≥3: 26 | Good | |
Yang et al23 | 2012 | 29 | 148 | 20 | 128 | 53 | 86 | PP/SP | 51 | ··· | ··· | NS | NS | Good |
Stein et al5 | 2009 | 11.4 | 1655 | 433 | 1222 | 64.4 | 83 | PP | ··· | 46b | ··· | <3: 69b, ≥3: 31 | Good | |
Smith et al24 | 2011 | 31 | 427 | 112 | 315 | 58 | 79 | PP | 27 | 46b | ··· | <3: 82b, ≥3: 18 | Good | |
Kraaier et al25 | 2013 | 12 | 861 | 207 | 654 | 62.7 | 79 | PP | 25 | ··· | ··· | NS | NS | Good |
Hess et al26 | 2014 | 34.8 | 47 282 | 12 834 | 34 448 | 67 | NS | PP | 25 | ··· | ··· | <3: 63b, ≥3: 37 | Good | |
Caputo et al27 | 2016 | 46 | 156 | 78 | 78 | 65 | NS | SP | 39 | 27b | ··· | NS | NS | Good |
AA indicates antiarrhythmic; AF, atrial fibrillation; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; Med, goal‐directed medical therapy; NS, not specified; NSR, normal sinus rhythm; PP, primary prevention; SP, secondary prevention.
Newcastle‐Ottawa Quality Assessment Scale: poor <4, fair 5 to 6, good >7.
All patients.